Abdul Hannan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abdul Hannan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Sanan
Khyber Medical College
1 shared publication - Ahmed Abdul Rab
Department of Medicine, Nishtar Medical University, Multan, Pakistan
1 shared publication - Daniya Naveed
Karachi medical and dental college Karachi, Karachi, Pakistan
1 shared publication - Gayatri Brahmandam
Department of Medicine, Adichunchanagiri Institute of Medical Sciences, Mandya, India
1 shared publication - Ibrahim Khalil
Department of Medicine, Dhaka Medical College and hospital, Dhaka, Bangladesh
1 shared publication - Iqra Nawaz
Quaid-e-Azam Medical College, Bahawalpur, Pakistan
1 shared publication
Latest Publications
- 14 January 2026
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 126, 116-127
Mortality Trends for Aortic Aneurysm Rupture in the United States, 1999–2020: A Population-Based Observational Study Using CDC WONDER
- 14 January 2026
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 126, 116-127
Mortality Trends for Aortic Aneurysm Rupture in the United States, 1999–2020: A Population-Based Observational Study Using CDC WONDER
- 28 October 2025
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- p. 1-9
Temporal Trends in Gender, Racial, and Geographic Disparities of Heart Failure and Pulmonary Embolism-Related Mortality Among Adults in the United States, 1999–2020: A Retrospective Analysis
Background Heart Failure (HF) and Pulmonary Embolism (PE)-related mortality rates are increasing annually in the United States. Disparities in cardiovascular outcomes are well established across ethnicity, sex and geography. The study aims to analyze the mortality trends in HF and PE-related mortality and the disparities in sex, race and geagraphy in the US (1999–2020). Methods The study analyzed HF and PE-related mortality rates using death certificate data from the CDC WONDER database under Multiple Causes of Death (MCOD) file. Age-Adjusted Mortality Rates (AAMR) per 100,000 population, Annual Percent Changes (APCs) and Confidence Intervals (CIs) were calculated. Data were further stratified by year, sex, race, and geographic region. Results This study examined 60,072 deaths related to HF and PE among U.S. adults aged 25–85 + years. The AAMR increased from 1.1 (95% CI: 1.05–1.15) to 1.88 (95% CI: 1.83–1.93), with a sharp rise from 2018 to 2020 (APC = 12.14). The total number of deaths increased from 1,980 to 5,026. Mortality was higher among females (56.07%) than males (43.93%), and men exhibited higher AAMRs (1.35) than females (1.2), AAMRs among men increased from 1.25 to 2.14 (2013–2020, APC = 7.21), AAMRs among females increased from 1.3 to 1.66 (2018–2020, APC = 12.16). Racial disparities were evident, with non-Hispanic (NH) Black individuals having the highest AAMR (2.10), followed by NH Whites (AAMR = 1.24), NH American Indian or Alaska Natives (AAMR = 1.13) and Hispanics (AAMR = 0.41) Geographic differences were notable, with the Midwest Region having the highest AAMR 4 (1.38–1.42). Wyoming recorded the highest AAMR (2.05), while Hawaii had the lowest (0.65). States Texas (AAMR = 1.55) and California (AAMR = 1.12) contributed the highest total deaths. Conclusion HF and PE-related AAMR increased in the US from 1999 to 2020. AAMRs were seen more in men, NH black Africans, and southern regions.
- 28 October 2025
- Published by Springer Nature in Journal of Racial and Ethnic Health Disparities
- p. 1-9
Temporal Trends in Gender, Racial, and Geographic Disparities of Heart Failure and Pulmonary Embolism-Related Mortality Among Adults in the United States, 1999–2020: A Retrospective Analysis
Background Heart Failure (HF) and Pulmonary Embolism (PE)-related mortality rates are increasing annually in the United States. Disparities in cardiovascular outcomes are well established across ethnicity, sex and geography. The study aims to analyze the mortality trends in HF and PE-related mortality and the disparities in sex, race and geagraphy in the US (1999–2020). Methods The study analyzed HF and PE-related mortality rates using death certificate data from the CDC WONDER database under Multiple Causes of Death (MCOD) file. Age-Adjusted Mortality Rates (AAMR) per 100,000 population, Annual Percent Changes (APCs) and Confidence Intervals (CIs) were calculated. Data were further stratified by year, sex, race, and geographic region. Results This study examined 60,072 deaths related to HF and PE among U.S. adults aged 25–85 + years. The AAMR increased from 1.1 (95% CI: 1.05–1.15) to 1.88 (95% CI: 1.83–1.93), with a sharp rise from 2018 to 2020 (APC = 12.14). The total number of deaths increased from 1,980 to 5,026. Mortality was higher among females (56.07%) than males (43.93%), and men exhibited higher AAMRs (1.35) than females (1.2), AAMRs among men increased from 1.25 to 2.14 (2013–2020, APC = 7.21), AAMRs among females increased from 1.3 to 1.66 (2018–2020, APC = 12.16). Racial disparities were evident, with non-Hispanic (NH) Black individuals having the highest AAMR (2.10), followed by NH Whites (AAMR = 1.24), NH American Indian or Alaska Natives (AAMR = 1.13) and Hispanics (AAMR = 0.41) Geographic differences were notable, with the Midwest Region having the highest AAMR 4 (1.38–1.42). Wyoming recorded the highest AAMR (2.05), while Hawaii had the lowest (0.65). States Texas (AAMR = 1.55) and California (AAMR = 1.12) contributed the highest total deaths. Conclusion HF and PE-related AAMR increased in the US from 1999 to 2020. AAMRs were seen more in men, NH black Africans, and southern regions.
- Open Access
- 9 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8434-8442
Long-term proton pump inhibitor use and risk of dementia: a focused review on pantoprazole
Background: Proton pump inhibitors (PPIs) are widely prescribed for acid-related disorders, yet concerns about their long-term effects on cognitive function persist. Emerging evidence suggests a possible association between prolonged PPI use and increased dementia risk, though findings remain inconclusive. This narrative review focuses on pantoprazole, a PPI with unique pharmacokinetics, to assess its potential role in dementia development. Methods: A systematic search was conducted using PubMed and PubMed Central with keywords including “dementia,” “proton pump inhibitors,” “Alzheimer’s disease,” and “adverse effects of PPIs,” etc. Studies published from 1 January 2002 to 31 December 2024 were included, focusing on clinical trials, cohort studies, meta-analyses, and systematic reviews. Two independent reviewers assessed eligibility by screening abstracts and full texts, excluding case reports, conference abstracts, and editorial letters. Results: Thirteen studies investigating the association between PPI use and dementia were included. Observational studies in Asian populations reported an increased risk, whereas Western studies showed inconsistent results. Mechanistic insights suggest PPIs may contribute to dementia through amyloid-β accumulation, vitamin B12 deficiency, and endothelial dysfunction. Mendelian randomization studies and meta-analyses found no statistically significant association. Pantoprazole’s prolonged acid suppression may differentially influence dementia risk. Conclusion: Evidence on the link between long-term PPI use and dementia is conflicting, with variability in study populations and methodological limitations. Further prospective studies and randomized controlled trials are needed to clarify causality. Clinicians should exercise caution, reassess long-term PPI necessity, and consider alternatives to mitigate potential risks.
- 9 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8434-8442
Open AccessLong-term proton pump inhibitor use and risk of dementia: a focused review on pantoprazole
Background: Proton pump inhibitors (PPIs) are widely prescribed for acid-related disorders, yet concerns about their long-term effects on cognitive function persist. Emerging evidence suggests a possible association between prolonged PPI use and increased dementia risk, though findings remain inconclusive. This narrative review focuses on pantoprazole, a PPI with unique pharmacokinetics, to assess its potential role in dementia development. Methods: A systematic search was conducted using PubMed and PubMed Central with keywords including “dementia,” “proton pump inhibitors,” “Alzheimer’s disease,” and “adverse effects of PPIs,” etc. Studies published from 1 January 2002 to 31 December 2024 were included, focusing on clinical trials, cohort studies, meta-analyses, and systematic reviews. Two independent reviewers assessed eligibility by screening abstracts and full texts, excluding case reports, conference abstracts, and editorial letters. Results: Thirteen studies investigating the association between PPI use and dementia were included. Observational studies in Asian populations reported an increased risk, whereas Western studies showed inconsistent results. Mechanistic insights suggest PPIs may contribute to dementia through amyloid-β accumulation, vitamin B12 deficiency, and endothelial dysfunction. Mendelian randomization studies and meta-analyses found no statistically significant association. Pantoprazole’s prolonged acid suppression may differentially influence dementia risk. Conclusion: Evidence on the link between long-term PPI use and dementia is conflicting, with variability in study populations and methodological limitations. Further prospective studies and randomized controlled trials are needed to clarify causality. Clinicians should exercise caution, reassess long-term PPI necessity, and consider alternatives to mitigate potential risks.